Increases in Acute Hepatitis C Virus Infection Related to a Growing Opioid Epidemic and Associated Injection Drug Use, United States, 2004 to 2014

American Journal of Public Health

Volumn 108, Issue 2, 2018, Pages 175-181

  Zibbell, Jon E ^a   Asher, Alice K ^b   Patel, Rajiv C ^c   Kupronis, Ben ^d   Iqbal, Kashif ^b   Ward, John W ^d   Holtzman, Deborah ^e  

^a RTI INTERNATIONAL   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIAMORPHINE; NARCOTIC ANALGESIC AGENT; PRESCRIPTION DRUG; STREET DRUG;

HEALTH SURVEY; HEPATITIS C; HUMAN; INCIDENCE; SUBSTANCE ABUSE; UNITED STATES;

ANALGESICS, OPIOID; HEPATITIS C; HEROIN; HUMANS; INCIDENCE; POPULATION SURVEILLANCE; PRESCRIPTION DRUGS; STREET DRUGS; SUBSTANCE ABUSE, INTRAVENOUS; UNITED STATES;

EID: 85040545033     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2017.304132     Document Type: Article

References (30)

1. Ly KN, Hughes EM, Jiles RB, Holmberg SD. Rising mortality associated with hepatitis C virus in the United States, 2003-2013. Clin Infect Dis. 2016;62(10):1287–1288.
2. Centers for Disease Control and Prevention. Hepatitis C. Available at https://www.cdc.gov/hepatitis/hcv/index.htm. Accessed July 7, 2016.
3. Hagan H, Pouget E, Des Jarlais D, Lelutiu-Weinberger C. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol. 2008;168(10): 1099–1109.
4. Paintsil E, He H, Peters C, Lindenbach BD, Heimer R. Survival of hepatitis C virus in syringes: implication for transmission among injection drug users. J Infect Dis. 2010; 202(7):984–990.
5. Thorpe LE, Ouellet LJ, Hershow R, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol. 2002;155(7):645–653.
6. Amon JJ, Garfein RS, Ahdieh-Grant L, et al. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004. Clin Infect Dis. 2008; 46(12):1852–1858.
7. Binka M, Paintsil E, Patel A, Lindenbach BD, Heimer R. Survival of hepatitis C virus in syringes is dependent on the design of the syringe-needle and dead space volume [published correction appears in PLoS One 2015;10(12): e0146088]. PLoS One. 2015;10(11):e0139737.
8. Bruneau J, Roy E, Arruda N, Zang G, Jutras-Aswad D. The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users. Addiction. 2012;107(7):1318–1327.
9. Zibbell JE, Hart-Malloy R, Barry J, Fan L, Flanigan C. Risk factors for HCV infection among young adults in rural New York who inject prescription opioid analgesics. Am J Public Health. 2014;104(11):2226–2232.
10. Centers for Disease Control and Prevention. Surveillance for viral hepatitis—United States, 2014. Available at http://www.cdc.gov/hepatitis/statistics/2014surveillance/pdfs/2014hepsurveillancerpt.pdf. Accessed July 7, 2016.
11. Zibbell JE, Iqbal K, Patel RC, et al. Increases in hepatitis C virus infection related to injection drug use among persons aged £30 years—Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012. MMWR Morb Mortal Wkly Rep. 2015;64(17):453–458.
12. Centers for Disease Control and Prevention. Hepatitis C virus infection among adolescents and young adults: Massachusetts, 2002-2009. MMWR Morb Mortal Wkly Rep. 2011;60(17):537–541.
13. Centers for Disease Control and Prevention. Notes from the field: hepatitis C virus infections among young adults—rural Wisconsin, 2010. MMWR Morb Mortal Wkly Rep. 2012;61(19):358.
14. Centers for Disease Control and Prevention. Use of enhanced surveillance for hepatitis C virus infection to detect a cluster among young injection-drug users—New York, November 2004-April 2007. MMWR Morb Mortal Wkly Rep. 2008;57(19):517–521.
15. Peters PJ, Pontones P, Hoover KW, et al. HIV infection linked to injection use of oxymorphone in Indiana, 2014-2015. N Engl J Med. 2016;375(3):229–239.
16. Centers for Disease Control and Prevention. National Notifiable Diseases Surveillance System. Available at https://wwwn.cdc.gov/nndss/conditions/hepatitis-cacute. Accessed July 12, 2016.
17. US Census Bureau. Population and housing unit estimates. Available at http://www.census.gov/popest. Accessed May 19, 2017.
18. Substance Abuse & Mental Health Data Archive. Treatment Episode Data Set: Admissions (TEDS-A-2013), Parent Series details. Available at https://datafiles.samhsa.gov/study/treatment-episode-data-set-admissions-teds-2013-nid16874. Accessed June 19, 2016.
19. Suryaprasad AG, White JZ, Xu F, et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012. Clin Infect Dis. 2014;59(10):1411–1419.
20. Center for Behavioral Health Statistics and Quality. Results from the 2014 National Survey on Drug Use and Health: detailed tables. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2015.
21. Koneru A, Nelson N, Hariri S, et al. Increased hepatitis C virus (HCV) detection in women of childbearing age and potential risk for vertical transmission—United States and Kentucky, 2011-2014. MMWR Morb Mortal Wkly Rep. 2016;65(28):705–710.
22. Ko JY, Patrick SW, Tong VT, Patel R, Lind JN, Barfield WD. Incidence of neonatal abstinence syndrome—28 states, 1999–2013. MMWR Morb Mortal Wkly Rep. 2016; 65(31):799–802.
23. Levy B, Spelke B, Paulozzi LJ, et al. Recognition and response to opioid overdose deaths—New Mexico, 2012. Drug Alcohol Depend. 2016;167:29–35.
24. Hedegaard H, Warner M, Mineno AM. Drug overdose deaths in the United States, 1999-2015. NCHS data brief no. 273. Hyattsville, MD: National Center for Health Statistics. Available at https://www.cdc.gov/nchs/products/databriefs/db273.htm. Accessed November 21, 2017.
25. Pouget ER, Friedman SR, Cleland CM, Tempalski B, Cooper HL. Estimates of the population prevalence of injection drug users among Hispanic residents of large US metropolitan areas. J Urban Health. 2012;89(3):527–564.
26. Centers for Disease Control and Prevention. National Notifiable Diseases Surveillance System, hepatitis C, acute 2012 case definition. Available at https://wwwn.cdc.gov/nndss/conditions/hepatitis-c-acute/case-definition/2012. Accessed April 25, 2017.
27. van Panhuis WG, Paul P, Emerson C, et al. A systematic review of barriers to data sharing in public health. BMC Public Health. 2014;14(1):1144.
28. Centers for Disease Control and Prevention. Viral hepatitis surveillance—United States, 2009. Available at https://www.cdc.gov/hepatitis/statistics/2009surveillance/index.htm. Accessed May 12, 2017.
29. National Academies of Sciences Engineering, and Medicine. A National Strategy for the Elimination of Hepatitis B and C. Washington, DC: National Academies Press; 2017.
30. Centers for Disease Control and Prevention. Division of Viral Hepatitis (DVH) strategic plan, 2016–2020: bringing together science and public-health practice for the elimination of viral hepatitis. Available at http:// wwwcdcgov/hepatitis/pdfs/dvh-strategicplan2016-2020.pdf. Accessed April 26, 2017.